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MYELOID NEOPLASIA
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*Maria E. Figueroa,1 *Bas J. Wouters,2 Lucy Skrabanek,3 Jacob Glass,4 Yushan Li,1 Claudia A. J. Erpelinck-Verschueren,2
Anton W. Langerak,5 Bob Lo¨wenberg,2 Melissa Fazzari,6 John M. Greally,4,7 Peter J. M. Valk,2 Ari Melnick,1 and Ruud Delwel2
1Department of Medicine (Hematology Oncology Division), Weill Cornell Medical College, New York, NY; 2Department of Hematology, Erasmus University
Medical Center, Rotterdam, The Netherlands; 3Department of Physiology and Biophysics and HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for
Computational Biomedicine, Weill Cornell Medical College, New York, NY; 4Department of Molecular Genetics, Albert Einstein College of Medicine, New York,
NY; 5Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands; and Departments of 6Epidemiology and Population Health
and 7Medicine, Albert Einstein College of Medicine, New York, NY
Acute myeloid leukemia is a heteroge-
neous disease from the molecular and
biologic standpoints, and even patients
with a specific gene expression profile
may present clinical and molecular heter-
ogeneity. We studied the epigenetic pro-
files of a cohort of patients who shared a
common gene expression profile but dif-
fered in that only half of them harbored
mutations of the CEBPA locus, whereas
the rest presented with silencing of this
gene and coexpression of certain T-cell
markers. DNA methylation studies re-
vealed that these 2 groups of patients
could be readily segregated in an unsu-
pervised fashion based on their DNA
methylation profiles alone. Furthermore,
CEBPA silencing was associated with the
presence of an aberrant DNA hypermeth-
ylation signature, which was not present
in the CEBPA mutant group. This aber-
rant hypermethylation occurred more fre-
quently at sites within CpG islands.
CEBPA-silenced leukemias also displayed
marked hypermethylation compared with
normal CD34 hematopoietic cells,
whereas CEBPA mutant cases showed
only mild changes in DNA methylation
compared with these normal progenitors.
Biologically, CEBPA-silenced leukemias
presented with a decreased response to
myeloid growth factors in vitro. (Blood.
2009;113:2795-2804)
Introduction
Aberrant transcriptional programming is a hallmark of leukemogen-
esis.1 Although it is well accepted that transcription factors play a
crucial role in directing lineage decisions during normal hematopoi-
esis, it is becoming increasingly clear that epigenetic modifications
also have a profound influence on regulation of gene transcription.2
It is probable that these levels of regulation are not mutually
exclusive; for instance, it has been shown that certain lineage-
specific transcription factors such as PU.1 can guide the locations
in the genome that become methylated.3 Still, it remains largely
unknown how DNA methylation patterns are determined.
The basic leucine zipper transcription factor CCAAT/enhancer
binding protein- (C/EBP) is a key regulator of hematopoietic
stem cell homeostasis and normal myeloid development, and
disruption of its normal function has been implicated in myeloid
malignancies.4,5 The CEBPA gene is reported to be mutated in 5%
to 15% of all cases of acute myeloid leukemia (AML).6-9 Further-
more, it can also be aberrantly repressed by oncogenes, such as
AML1-ETO,10 or modified at the posttranslational level through
the actions of FLT3 and Ras.11,12 Methylation of the CEBPA
promoter has also been reported in AML as well as in other
malignancies.13-16
In a genome-wide gene expression profiling study of 285 cases
of de novo AML, it was found that AMLs with mutations in CEBPA
(CEBPAmut) featured gene expression signatures that clearly dis-
criminated them from other AML subgroups.17 However, a small
subset of leukemias without CEBPA gene aberrations was found to
express a similar gene expression signature. It was found that a
frequent characteristic in this subset of leukemias was CpG
hypermethylation of the CEBPA proximal promoter, which was
associated with silencing of CEBPA expression (CEBPAsil). Subse-
quent analyses revealed an immature mixed myeloid/T-lymphoid
immunophenotype and frequent NOTCH1 mutations as additional
characteristics of these leukemias.16
Although these studies suggested a role for epigenetic silencing
of CEBPA in the leukemic phenotype, they also raised several
questions: (1) Is silencing of CEBPA through hypermethylation an
isolated event or rather one aspect of broader epigenetic modifica-
tions? (2) Are particular biologic pathways specifically involved in
the disease phenotype? (3) Are these leukemias more similar to
T-cell acute lymphoblastic leukemia (T-ALL) than AML? To
address these questions and further investigate the role of DNA
methylation in this subgroup of leukemias, we analyzed DNA
methylation on a genome-wide scale in CEBPAmut and CEBPAsil
patients and also in T-ALL. We found that CEBPA methylation was
associated with aberrant hypermethylation of many genes com-
pared with CEBPAmut AMLs or to normal CD34 hematopoietic
progenitor cells. These hypermethylated genes included many
factors involved in transcriptional regulation and mesenchymal cell
differentiation and harbored several common genomic features.
The epigenetic signature of this form of leukemia was distinct from
T-ALL. Taken together, these data suggest the existence of a
subtype of immature myeloid/T-lymphoid leukemia in which
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aberrant epigenetic programming results in a disease that is
refractory to normal environmental signals and antileukemia
therapy.
Methods
Patient samples
Twenty-five acute leukemia cases were studied. They included 14 of
15 leukemias from the original gene expression cluster 4 described by Valk
et al,17 and represented 8 cases with CEBPA mutations and 6 cases with
silenced CEBPA characteristics. Two additional cases of CEBPA-silenced
leukemias, which had been identified in a second AML cohort and
described in our previous work,16 were also studied. Nine adult T-ALLs
were selected, representing various stages of maturation. Characteristics of
these T-ALL cases are given in Table S1 (available on the Blood website;
see the Supplemental Materials link at the top of the online article). Normal
CD34 progenitor cells were purified from bone marrow specimens from
8 healthy donors: 4 acquired from the Translational Trials Development and
Support Laboratory, Cincinnati Children’s Hospital (Cincinnati, OH) and
4 purchased from Allcells (Emeryville, CA). This research was approved by
the institutional review boards at Albert Einstein College of Medicine, Weill
Cornell Medical College, and Erasmus University, and donor informed
consent was obtained in accordance with the Declaration of Helsinki.
DNA methylation analysis by HELP
High-molecular-weight DNA was isolated from white cell fractions using a
standard high salt procedure, and the HELP (HpaII tiny fragment enrich-
ment by ligation-mediated PCR) assay was carried out as previously
described.18,19 All samples for microarray hybridization were processed at
the Roche-NimbleGen Service Laboratory. Samples were labeled using
Cy-labeled random primers (9 mers) and then hybridized onto a human
HG17 custom-designed oligonucleotide array (50-mers) covering
25 626 HpaII-amplifiable fragments located at gene promoters and im-
printed regions. HpaII-amplifiable fragments are defined as genomic
sequences contained between 2 flanking HpaII sites found within 200 to
2000 bp from each other. Each HpaII-amplifiable fragment on the array is
represented by 15 individual probes distributed randomly across the
microarray slide. Scanning was performed using a GenePix 4000B scanner
(Molecular Devices, Sunnyvale, CA) as previously described.20 Quality
control and data analysis of HELP microarrays were performed as described
by Thompson et al.21 DNA methylation was measured as the log(HpaII/
MspI) ratio, where HpaII reflects the hypomethylated fraction of the
genome and MspI represents the whole genome reference. All microarray
data have been submitted to the Gene Expression Omnibus (GEO)
repository (accession number GSE14417).22
Gene expression microarrays
Detailed protocols are provided in Document S1.
Microarray data analysis
Unsupervised clustering of HELP and gene expression data by principal
component analysis were performed using the statistical software R version
2.6.2 and the BioConductor package MADE4.23 Supervised analysis was
carried out using a moderated t test with a significance level of P less than
.001 (all P values were still significant at P  .05 after correcting for
multiple testing using the Benjamini-Hochberg approach) and fold change
more than 2 for gene expression. In the case of the methylation data, an
absolute difference in methylation more than 2 between the means of the
2 populations was required to increase the likelihood of detection of
biologically significant changes in methylation levels.
Quantitative DNA methylation analysis by MassARRAY
EpiTyping
This analysis is described in Document S1.
CEBPA status classifier
The DNA methylation status for each HpaII-amplifiable fragment was
categorized as follows: fragments having log 2 (HpaII/MspI) less than 0
were considered methylated, and those with log 2 ratios greater than 0 were
considered hypomethylated. AML samples were categorized according to
their CEBPA locus mutation status, and a Fisher exact test was performed at
each locus to rank its predictive ability. Cutoffs for perfect, intermediate,
and poor classifiers were set at P values of 1.55e4 (which corresponds to
Fisher exact P value based on perfect classification for this sample size), .2,
and more than .2, respectively. The use of .20 as the threshold was set
arbitrarily but represents an acceptable P value range for intermediate
classification ability given the sample size.
Sequence analysis
Sequence retrieval, repeat element analysis, and motif analysis are de-
scribed in Document S1.
In vitro cultures and thymidine incorporation assay
These are described in Document S1.
Results
CEBPA silencing is associated with an aberrant DNA
methylation signature
To determine whether DNAmethylation of the CEBPA promoter was an
isolated event or part of widespread aberrant epigenetic gene silencing,
we carried out a genome-wide DNA methylation study. For this, we
used the HELP (HpaII tiny fragment enrichment by ligation-mediated
PCR) assay,19 a method that accurately identifies the DNA methylation
level of 25 626 HpaII-amplifiable fragments annotated to approximately
14 000 human gene promoters. All of the methylation profiles passed a
rigorous quality control and normalization procedure as described by
Thompson et al.21 The accuracy in detecting variance in DNA methyl-
ation was validated by performing single-locus quantitative EpiTyping
on a panel of 10 genes (Figure S1).
We first assessed the underlying variability in DNA methylation
of 8 cases with CEBPAsil and 8 cases with CEBPAmut using principal
component analysis (PCA). This analysis demonstrated separate
clustering of the 2 groups, indicating that these groups of patients
are epigenetically distinct (Figure 1A). The CEBPA locus itself is
represented on the HELP microarray by 4 HpaII-amplifiable
fragments. These fragments correspond to nucleotides 1334 to
1980, 857 to 1113, 1569 to 1819, and 2247 to 2863,
relative to the transcription start site. Analysis of these fragments
confirmed our previous observations: whereas the region
was unmethylated in all CEBPAmut cases, it was highly methylated
in all CEBPAsil cases (2-tailed t test: P  1e9; Figure 1B,C).
DNA methylation of the CEBPA locus was confirmed using
MassARRAY EpiTyping (Sequenom, San Diego, CA; Figure 1D).
To identify the genes other than CEBPA that were differentially
methylated between the 2 groups, we performed a supervised analysis.
This comparison identified 567 HpaII-amplifiable fragments (474 genes),
which included CEBPA. Strikingly, almost all (n 470) of these genes
were hypermethylated in the CEBPAsil leukemias. Hypermethylation is
thus a specific biologic feature of these leukemias that distinguishes
them from CEBPAmut cases. Only 4 probe sets were hypomethylated in
CEBPAsil leukemias, which included LCK and TRBC1, T-cell genes that
we previously reported were overexpressed in this group of patients16
(Figure 1E,F; Table S2).
Using Ingenuity Pathway Analysis software (Redwood City,
CA), we carried out a network analysis to investigate whether
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genes in this differentially methylated signature interrelated with
each other. Interestingly, the 2 top-scoring networks were centered
around CEBPA and NFB and could almost exclusively be
generated using genes that were differentially methylated (32 of 35
and 24 of 35 genes in the networks, respectively). The fact that the
majority of genes in the network were affected by aberrant
methylation is highly suggestive of the biologic importance of this
observation. An additional network involved several bone morpho-
genetic protein (BMP) factors (in which 25 of 34 genes were
involved), suggesting potential involvement of transforming growth
factor- signaling in these tumors as well. The genes involved in
the 3 top-scoring networks are listed in Table 1 and Figure S2.
Among the most represented gene ontology terms within the
hypermethylated signature were regulation of transcription and
mesenchymal cell development (Table 2). Despite the association
of some CEBPAsil cases with Notch1 activating mutations, we did
not find a significant overlap between this hypermethylated gene
signature and the Notch1 signature reported by Palomero et al.24
CEBPAsil and CEBPAmut leukemia cells are epigenetically
distinct from normal bone marrow CD34 cells
Does hypermethylation in CEBPAsil leukemic blasts represent
aberrant epigenetic programming compared with normal CD34
cells? In a supervised comparison of CEBPAsil leukemia cells with
CD34 healthy donor bone marrow fractions (n  8), a large
number of differentially methylated loci (1035 HpaII-amplifiable
fragments, 876 unique genes) was found. Similarly as in the
previous analyses, most of the genes (841 of 876) were hypermethy-
lated in the CEBPAsil leukemia subgroup (Figure 2A,B). Moreover,
281 of these 876 genes appeared to be hypermethylated both
compared with normal CD34 cells and to CEBPAmut leukemias,
indicating that aberrant hypermethylation of these genes occurred
exclusively in CEBPAsil cases. These included, among others, the
tumor suppressors CDKN2B and IRF8, the cell cycle regulator
MyoD1, and the WNT signaling antagonist SFRP1. Loss of all
these genes has been previously implicated in tumorigenesis.25-29
Furthermore, hypermethylation of the promoter regions of CDKN2B,
MyoD1, and SFRP1 has been described in association with several
forms of leukemia.30-35 A complete list of the genes exclusively
methylated in the CEBPAsil subgroup versus normal CD34 cells is
provided in Table S3. Both of the proximal HpaII-amplifiable
fragments for the CEBPA locus reached statistical significance and
showed hypermethylation in the CEBPAsil group versus the normal
CD34 cells, with an absolute methylation change slightly below
our set threshold of 2 (change, 1.63 and 1.99; Figure S3). Only
45 of the 1035 HpaII-amplifiable fragments were hypomethylated
Figure 1. A unique methylation profile distinguishes CEBPAsil from CEBPAmut AML. (A) Principal component analysis of DNA methylation data using the HELP assay on
8 CEBPAsil and 8 CEBPAmut AML cases revealed that the cases were readily segregated into 2 clusters, which matched exactly with CEBPA status. (B) Heatmap representation
of the 4 probe sets annotated to the CEBPA locus on the HELP microarray; cases are clustered according to their methylation status. CEBPAsil cases cluster together (left
node), and all show higher levels of methylation for at least 3 of the 4 probe sets. (C) Representation of the positioning of the 4 probe sets relative to the genomic localization of
the CEBPA locus and its CpG island on chromosome 19. HELP methylation values for each leukemia case are represented in one row; the y-axis represents centered log2
(HpaII/MspI) ratios. Positive values correspond to hypomethylated fragments, whereas a negative deflection reflects a methylated fragment. The first 8 rows correspond to the
CEBPAsil cases (in red), and the remaining rows to the CEBPAmut cases (in blue). (D) Heatmap representing the DNA methylation status at 5 different regions of the CEBPA
locus. Percentage cytosine methylation was determined at these regions for all cases using MassARRAY EpiTyper. (E) Two-dimensional hierarchical clustering of genes
differentially methylated between the 2 leukemia subgroups, illustrated by a heatmap. Supervised analysis identified 567 HpaII-amplifiable fragments (P  .001 and absolute
difference in methylation  2). Cases are represented in the columns; probe sets are represented in the rows. CEBPAsil cases are clustered in the left node and display high
methylation levels for 563 HpaII-amplifiable fragments. (Right) Heatmap representation of the 4 probe sets that displayed the opposite behavior, ie, relative hypomethylation in
CEBPAsil leukemia. (F) A plot of methylation difference between CEBPAsil and CEBPAmut cases (x-axis) versus statistical significance (y-axis) shows the marked asymmetry of
the 2 branches, illustrating the overall tendency to higher methylation levels in the CEBPAsil cases. Red points represent probe sets that reached both criteria for differential
methylation on our analysis (P  .001 and absolute methylation difference  2).
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in the CEBPAsil cases and hypermethylated in normal CD34 cells.
These loci included the T-cell genes CD3D and TRBC1.
In the CEBPAmut group, abnormal methylation was less abundant,
with only 322 HpaII-amplifiable fragments (286 unique genes) detected
as differentially methylated with respect to normal CD34 cells.
Moreover, the difference in DNA methylation was distributed evenly,
where approximately half of these probe sets were hypermethylated and
the other half hypomethylated (Figure 2C,D). This finding indicates that
the markedly increased prevalence of abnormal promoter hypermethyl-
ation is highly specific to CEBPAsil cases among the CEBPA gene
expression signature AML patients.
When we compared both subgroups of leukemias with normal
CD34 cells, 100 unique genes were found to be aberrantly
methylated in the leukemia samples. These included CDKN2A,
CCR7, MT2A, and NOS3 and were all linked together in a
cancer/cell signaling network through Ingenuity Pathway Analysis
(Table S4). This finding suggests that aberrant hypermethylation of
these genes is a common event in both these leukemogenic
processes and therefore deserves further study.
Hypermethylation in CEBPAsil leukemias is localized mainly to
CpG islands and CG clusters
To obtain further insight into the differences in methylation profiles
between CEBPAsil leukemias and CEBPAmut AMLs, we next asked
whether the observed differences in DNA methylation were found
at either CpG islands or CG clusters36 more frequently than
expected based on the distribution of all fragments on the arrays.
For this analysis, we categorized all HpaII-amplifiable fragments
on the HELP array into 2 categories: those that overlapped with a
known CpG island or CG cluster and those that did not. We found
15 043 of 25 626 (58%) fragments to be completely located within,
or partly overlapping with, CG clusters. Furthermore, 10 006 of
25 626 (39%) fragments were located in or partly overlapped with
CpG islands. Of the 567 fragments identified as differentially
methylated between the 2 leukemia groups, 450 (79.3%) over-
lapped with at least one CG cluster, whereas 318 (56.1%)
overlapped with a CpG island (Figure 3A). Thus, there was a
significant enrichment in the signature for fragments overlapping
with either CpG islands (56% vs 39%) as well as with CG clusters
(79% vs 58%, proportion test; P  .001 for both), which is
consistent with their proposed regulatory functions. On the other
hand, these analyses show that a subset of the differentially
methylated HpaII-amplifiable fragments did not overlap with CpG
islands or CG clusters, underscoring the importance of extending
DNA methylation studies beyond those areas of the genome
containing CpG islands and CG clusters.
Next we categorized each HpaII-amplifiable fragment into
methylated or hypomethylated and ranked them by their ability to
discriminate between CEBPAmut and CEBPAsil cases (summarized
by Fisher exact test P value). Fragments were then grouped into
perfect, intermediate, or poor classifiers. A total of 66 fragments
were categorized as perfect classifiers. Of these, 59 (89%) were
located in CG clusters, 2 of which were also annotated as
CpG islands). All 66 fragments exhibit consistent methylation in
CEBPAsil cases and hypomethylation in CEBPAmut cases. Intermedi-
ate classifiers showed 78% of the fragments overlapping with CG
clusters, and only 56% of the poor classifiers overlapped with a CG
cluster (Figure 3B). Taken together, these data suggest that, among
differentially methylated genes, those that contain CpG islands or
clusters are most critical for defining the epigenetic signature of
CEBPAsil leukemia cases.
Hypermethylated promoters in CEBPAsil display specific
genomic features
We next examined whether genes susceptible to becoming methyl-
ated in CEBPAsil leukemias (compared with CEBPAmut) shared any
common genomic features. The regions spanning the 2-kb se-
quence upstream of the transcription start site of the 327 RefSeq
genes assigned to the differentially methylated 567 HpaII-
amplifiable fragments were retrieved. Next, these sequences were
compared with 2422 RefSeq gene promoter sequences (correspond-
ing to 2672 HpaII-amplifiable fragments) that were randomly
selected from the pool of HpaII-amplifiable fragments that did not
show any methylation difference between CEBPAsil and CEBPAmut.
Remarkably, hypermethylated genes were significantly less likely
to contain an Alu sequence than the control sequences. (Genes
containing Alu sequences: 60% [1453 of 2422] in the control
Table 1. Genes in the top 5 networks generated by the differentially methylated signature between CEBPAsil and CEBPAmut cases
No. Molecules in network
Focus
molecules
1 ADAMTS9, BARX1, CaMKII, CD180, CDH8, CHAT (includes EG:1103), DRD1, ELAVL3, FGF5, GNAS, GRIN2B, Gs-coupled receptor,
HTR7, IGHM, IGKC, ISL1, KRT17, KRT19, LHX3, MAP6, MEOX2, MNX1, NEFL, NEFM, NEUROD1, NEUROG3, NFkB, NKX2–2,
PAX1, PENK, PTPN13, RASGRF1, SATB2, TLR1, TLR8
32
2 CCK, CDKN2B, CDX2, CEBPA, COL4A1, cyclin A, E2f, EID2, ESX1, FOXG1, HGF, HIST1H2BJ, histone h3, insulin, IRF8, JTV1, LRAT,
Mapk, MARCKS (includes EG:4082), PGR, PITX2, POU2F3, POU3F2, PRLR, PTGFR, Rap1, Ras, RASA2, Rb, RELN, Rsk,
Smad1/5/8, SMPDL3A, TFAP2C, VEGF
24
3 alkaline phosphatase, ALPL, APOB, ATOH1, BMP, BMP3, BMP6, BMP7, FCGR2B, FOXA2, FOXC2, GSC, IL1, LDL, LPL, LRP6, MHC
class II, Mmp, MSX2, NELL1, ONECUT2, OSBPL6, P38 MAPK, PCDHGC3, PDGF BB, PLC-, PTHLH, SFRP1, SOX9, TGF-, UCP2,
Wnt, WNT2, WNT10B, ZAK
24
4 ACTN2, ADCY1, adenylate cyclase, AFAP1, -actinin, BDNF, Cacna1, CACNA1A, CACNA1E, CACNA1I, CACNA2D1, CALML5,
calmodulin, F actin, FOXL1, GAL, GALR1, GRIN3A, GRM1, Jnk, KCNN2, MARCKSL1, MBP, N-type calcium channel, NMDA receptor,
OCLN, OPRK1, PDLIM3, Pkc(s), PP2A, SLC6A2, SLC6A5, SNAP25, TAC1, voltage gated calcium channel
24
5 ADAM12, Akt, BRCA2, cofilin, creatine kinase, Creb, CYR61, EFNA5, EPHA, EPHA2, EPHA3, EPHA5, EPHA7, EPHA/B, GABBR2,
GDNF, GFRA1, GREM1, HABP4, HSPB8, HTR1B, IRS4, MAGI1, N-cor, NAE1, p70 S6k, Pdgf, PDGFC, PI3K, PIK3R1, PRKCZ, Rab5,
RET, Rock, TOP2B
23
Table 2. GO terms highly represented among the differentially
methylated genes between the 2 leukemia subgroups
Go term P Benjamini FDR
Mesenchymal cell development 4.1e5 1.9 e2 0.1
Neural crest cell differentiation 3.5e4 5.1e2 0.6
Regulation of transcription 1.4e4 4.6e2 0.2
Transcription DNA-dependent 2.8e4 4.7e2 0.5
RNA biosynthetic process 2.9e4 4.6e2 0.5
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sequences vs 26% [85 of 327] in the differentially methylated
sequences; Fisher exact test, P  2.2e16; Table 3.) This was the
only repeat element that showed a statistically significant distribu-
tion difference between the CEBPAsil signature and the randomly
selected control group. All other repeat sequences (eg, SINE/MIRs,
LINEs, or MERs) were present in approximately equal proportions.
We also looked at the promoter regions from 780 RefSeq genes
annotated to the 1035 HpaII-amplifiable fragments differentially
methylated between CEBPAsil leukemias versus normal CD34
bone marrow cells. We compared these with 3086 randomly
selected RefSeq promoters (corresponding to 4470 control HpaII-
amplifiable fragments). Once again, we found that differentially
methylated sequences were less likely to contain Alu elements
(60% in control sequences [1865 of 3086] vs 35% in the
differentially methylated sequences [277 of 780]; Fisher exact test,
P  2.2e16).
To determine whether a specific DNA sequence was associated
with the differentially methylated genes, we used the Finding
Informative Regulatory Elements (FIRE) algorithm37 to look at a
region containing 2 kb of sequence upstream of the reported
transcription start site. This analysis identified a nondegenerate
5	-CGCGCTC-3	 motif, which was significantly enriched in the
differentially methylated sequences compared with the control
sequences. The nondegenerate motif could be detected in 45% of
the differentially methylated sequences (147 of 327), whereas it
was found in less than 24% of the control sequences (574 of 2422;
Fisher exact test, P  3.3e13). An independent FIRE analysis
was carried out to study the promoter sequences of the RefSeq
genes annotated to the probe sets in the CEBPAsil versus normal
CD34 cell signature. Although this analysis discovered the same
nondegenerate motif as before, it was slightly less successful at
discriminating between the 2 groups (present in 32% of the
differentially methylated sequences [251 of 780] vs 20% of the
control sequences [628 of 3086]; Fisher exact test, P  8.7e12).
Although this motif does not correspond to a known transcription
factor binding site, FIRE annotated sequences containing this motif
as being associated with the Gene Ontology term GO:0043565,
involved in sequence-specific DNA binding (P  1e7). The
enrichment of this element within the hypermethylated signature is
suggestive of the existence of a putative DNA binding protein that
might participate in establishing this epigenetic signature.
Methylated genes in CEBPAsil leukemias tend to be expressed
at low levels
To determine the correlation of DNA methylation with gene
expression, we examined genome-wide mRNA transcript abun-
dance of the same CEBPAsil and CEBPAmut cases using Affymetrix
Figure 2. Aberrant hypermethylation is a feature of CEBPAsil
leukemia. (A) Two-dimensional hierarchical clustering of genes
differentially methylated between the CEBPAsil cases and normal
CD34 hematopoietic progenitors, illustrated by a heatmap.
Supervised analysis identified 1035 HpaII-amplifiable fragments
(P  .001 and absolute difference in methylation  2). Cases are
represented in the columns; probe sets are represented in the
rows. CEBPAsil cases are clustered in the left node and display
marked hypermethylation compared with the normals, as illus-
trated by the predominance of probe sets with low log2 (HpaII/
MspI) ratios. (B) Methylation difference between CEBPAsil and
normal CD34 cells (x-axis) versus statistical significance (y-axis)
plot with marked asymmetry of the 2 branches, reflecting the
tendency to higher methylation levels in this subgroup. Red points
represent probe sets that reached both criteria for differential
methylation in our analysis. (C) Two-dimensional hierarchical
clustering of genes differentially methylated between the
CEBPAmut AML and normal CD34 hematopoietic progenitors,
illustrated by a heatmap. Supervised analysis identified
322 probe sets (286 genes). CEBPAmut cases are clustered in the
left node and display equal components of hypermethylation and
hypomethylation compared with CD34 normal cells. (D) A plot of
methylation difference between mutant CEBPA and normal CD34
cells (x-axis) versus statistical significance (y-axis) shows symmet-
ric branches and less pronounced differences in methylation than
in the case of the silenced CEBPA subgroup. Red points repre-
sent probe sets that reached both criteria for differential methyl-
ation on our analysis.
EPIGENETIC BASIS OF LINEAGE INFIDELITY AML 2799BLOOD, 19 MARCH 2009  VOLUME 113, NUMBER 12
 For personal use only. at Erasmus MC Medical Library on July 21, 2009. www.bloodjournal.orgFrom 
HGU133 Plus 2.0 microarrays (Santa Clara, CA). An unsupervised
analysis using PCA indicated that, in contrast to DNA methylation
profiles, expression data did not result in segregation along the
major axes (Figure S4). Nevertheless, a supervised analysis
identified 587 probe sets, corresponding to 415 unique genes, as
differentially expressed between the 2 groups of leukemias, which
is in line with our previous findings16 (Figure 4A). Overlap
between the differentially methylated and differentially expressed
genes was only minimal (12 unique genes, including CEBPA itself).
This is consistent with our previous report showing that gene
expression and methylation profiling tend to capture biologic
variance in different sets of genes.18 Interestingly, signal intensities
of 62.5% of the genes detected as differentially hypermethylated
were measured at low abundance (intensity  log2[100]) in both
the CEBPAsil and the CEBPAmut groups. This may imply that these
genes are epigenetically silenced by DNA methylation in one group
and repressed through a different mechanism in the other. Along
these lines, expression levels for most of these genes were detected
at similarly low levels in an independent cohort of 400 AML cases
of other subtypes (data not shown). Methylation and gene expres-
sion were validated by MassARRAY on 15 genes for 3 CEBPAsil
and 4 CEBPAmut randomly selected cases and by quantitative
reverse-transcribed polymerase chain reaction on 10 of these genes
on 2 to 4 randomly selected cases from each group (Figure S5).
We next examined whether differential methylation in the genes
contained within the CEBPAsil versus CEBPAmut subtypes was more
correlated to expression levels than methylation occurring in
randomly selected subsets of genes. For this we determined the
correlation between transcript abundance and DNA methylation
status for the 474 genes differentially methylated between the
2 leukemia subgroups and compared it with that of genes annotated
to 600 randomly selected probe sets from the HELP microarray.
This comparison was repeated for 5 different randomly selected
groups of control probe sets. In every instance, the differentially
methylated genes showed a slightly stronger correlation with gene
expression levels (corresponding to a negative biologic correlation
between DNA methylation and gene expression) than the randomly
selected genes (Figure 4B).
CEBPAsil leukemias are epigenetically distinct from T-ALL
We hypothesized that CEBPAsil leukemias, although expressing
certain T-cell genes, are biologically and epigenetically not only
different from other AMLs, but also from T-ALL. To test this
hypothesis, we generated HELP profiles from a selection of
9 T-ALL cases from various maturation stages and compared those
with the methylation data of the CEBPAsil leukemias. Unsupervised
analysis of HELP using PCA resulted in separate clustering of the
CEBPAsil leukemias and the T-ALL cases (Figure 5A). A supervised
analysis identified 164 genes (199 HpaII-amplifiable fragments)
differentially methylated between the CEBPAsil leukemias and
T-ALLs (Figure 5B; Table S5). Specific analysis of the CEBPA
locus HpaII-amplifiable fragments indicated a mixed pattern in the
T-ALL samples. Whereas the majority of cases (n  6) showed
hypermethylation of the CEBPA proximal promoter, the remaining
3 did not (Figure S6). A similar separation of CEBPAsil leukemias
and T-ALL samples was observed based on gene expression data
(Figure 5C), indeed suggesting that CEBPAsil leukemias are
biologically and epigenetically distinct from T-ALL.
CEBPAsil leukemia cells are resistant to myeloid growth factors
To study whether silencing by methylation of the myeloid specific
transcription factor CEBPA corresponded with altered biologic
response to natural growth stimuli, we compared growth factor
stimulated 3H-TdR incorporation data obtained from pretreatment
CEBPAsil and CEBPAmut AML samples. Remarkably, CEBPAsil
leukemia cells showed little or no response to the myeloid growth
stimuli interleukin-3 (IL-3), granulocyte-macrophage colony-
stimulating factor (GM-CSF), or granulocyte colony-stimulating
factor (G-CSF), whereas CEBPAmut samples were particularly
sensitive to IL-3, but in certain cases also to GM-CSF (Figure 6;
Table S6). Whereas 2 of the CEBPAmut cases (3327 and 2192)
showed comparable results to the CEBPAsil cases, this did not
appear to be explained by their methylation profiles, and we think
Figure 3. Aberrant hypermethylation colocalizes to CpG islands and CG
clusters. (A) The genomic position of every HpaII-amplifiable fragment on the HELP
array was compared with the location of known CpG islands and CG clusters, and the
fragments on the array were divided into 2 categories: those overlapping with either
one of these genomic elements and those not overlapping. To determine whether the
differentially methylated genes between CEBPAsil and CEBPAmut leukemias were
enriched for either one of these types of elements, a proportions test was used to
compare the relative proportion of the 2 types of HpaII fragments in the signature
(overlapping vs not overlapping) to the relative proportion on the array. Stacking bars
are used to illustrate the finding of a significant enrichment for HpaII-amplifiable
fragments overlapping with CpG islands (right) and CG clusters (left) in the
hypermethylated signature of CEBPAsil leukemia, as it compares with the genomic
localization of all HpaII-amplifiable fragments on the HELP array. (B) Each HpaII-
amplifiable fragment represented on the HELP array was also categorized according
to its ability to discriminate between CEBPAsil and CEBPAmut leukemias as perfect,
intermediate, or poor classifiers, and the proportional amount of fragments overlap-
ping with CG clusters was calculated for each group of classifiers. Better classifiers
were more frequently associated with CG clusters.
Table 3. Alu elements are depleted from RefSeq promoters that
become hypermethylated in CEBPAsil leukemia
Silenced RefSeq
(n  327)
Random RefSeq
controls (n  2422)
P
(Fisher exact test)
Alu 85 (26%) 1453 (60%)  2.2e16
No Alu 242 (74%) 969 (40%)
2800 FIGUEROA et al BLOOD, 19 MARCH 2009  VOLUME 113, NUMBER 12
 For personal use only. at Erasmus MC Medical Library on July 21, 2009. www.bloodjournal.orgFrom 
that it is a reflection of the biologic heterogeneity of the group. In
contrast, both CEBPAsil and CEBPAmut patient cells showed weak
but significant response to factors that stimulate primitive cells, in
particular thrombopoietin or stem cell factor (Table S6). These data
are in agreement with previous data showing loss of the granulo-
cyte macrophage progenitors fraction and enrichment of hematopoi-
etic stem cell population in marrow of conditional Cebpa knockout
animals.38 Interestingly, we did not observe promoter hypermethyl-
ation of the genes encoding the receptors for IL-3, GM-CSF, or
G-CSF, suggesting other mechanisms of altered growth factor
response. Several of the growth factor receptors appeared to be
expressed as determined by gene expression profiling analysis,
although we observed significantly lower expression of CSF2RB,
the gene encoding the common beta chain of the receptors of
IL-3 and GM-CSF (P  .02, Wilcoxon rank-sum test) in
CEBPAsil patients compared with CEBPAmut AML samples.
Together, these data suggest that CEBPAsil cases reflect a more
primitive hematopoietic cell that does not enter cell cycle in
response to myeloid growth factors, an event that could be
associated with chemoresistance. In agreement, although the
numbers of patients were too small to rule out the influence of
covariables, the CEBPAsil patient outcomes (5-year overall survival
25%) were considerably worse than that of the CEBPAmut cases (5-year
overall survival 88%; log-rank test P .003).
Figure 4. DNA methylation and gene expression capture complementary information. (A) Two-dimensional hierarchical clustering of genes differentially expressed
between the 2 leukemia subgroups, illustrated by a heatmap. Supervised analysis identified 587 probe sets (415 genes) at a P  .001 and fold change more than 2. Cases are
represented in the columns; probe sets are represented in the rows. CEBPAsil cases are clustered in the right node, and CEBPAmut cases are clustered in the left node.
(B) Density (y-axis) plot for the gene-by-gene correlations (x-axis) between gene expression log intensity and log(HpaII/MspI) values. A positive correlation between these
2 measures translates into a negative biologic correlation, that is, hypermethylation in combination with lower expression levels, or hypomethylation in combination with higher
expression levels. In black, density plot for the correlation between expression and methylation for a set of 600 randomly selected probe sets. In red, density plot for the
correlation between expression and methylation measured by the 567 probe sets in the genes differentially methylated between the 2 subgroups. The shifting of the density plot
to the right reflects a tendency to a stronger correlation of DNA methylation with gene expression levels in this subset of genes. The figure is representative of 5 analyses, each
time using a different set of 600 randomly selected HpaII-amplifiable fragments for the calculation of correlations.
Figure 5. CEBPAsil leukemias differ genetically and epigenetically from T-ALL. (A) Principal component analysis of DNA methylation data comparing 8 immature acute
myeloid/T lymphoid CEBPAsil cases with a selection of 9 T-ALL cases representing a spectrum of maturation stages, showing separate clustering of the 2 groups of leukemias.
(B) Two-dimensional hierarchical clustering of genes differentially methylated between the CEBPAsil leukemias and the T-ALL cases, illustrated by a heatmap. Cases are
represented in the columns; probe sets are represented in the rows. Supervised analysis identified 213 differentially methylated probe sets (199 genes). CEBPAsil cases are
clustered in the left node and display a predominance of hypomethylated probe sets. (C) Principal component analysis of gene expression data for the same cases also
demonstrates separate clustering of the 2 groups of leukemias, indicating that these 2 groups display distinct expression profiles.
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Discussion
The subtype of immature myeloid/T-lymphoid leukemia reported
in this study was first captured as belonging to a larger group of
patients all sharing a specific gene expression signature (originally
designated as cluster 4).17 A subset of these patients was subse-
quently observed to harbor hypermethylation and silencing of the
CEBPA gene along with expression of T-cell genes.16 In the current
study, we applied integrated epigenetic profiling to explore in
greater depth the nature of this disease, and demonstrate that this is
indeed a biologic entity that is distinct from both AML and T-ALL
and has unique epigenetic, transcriptional, and biologic features.
Given the similarity in gene expression profiles of CEBPAsil and
CEBPAmut AML found initially, we were primarily interested in
determining whether DNA methylation profiles might more readily
discriminate these 2 groups. Along these lines, we have previously
shown that integrating information obtained from DNA methyl-
ation profiling and gene expression profiling in human leukemia
specimens could yield more in-depth insight into biologic differ-
ences between patients.18 We find that PCA, an unbiased method to
discriminate biologic differences, showed a marked separation
between epigenetic profiles of patients with mutant or silenced
CEBPA. This indicates that these are 2 biologically distinct entities,
which is further supported by the differences in growth factor
responses between the 2 leukemia subtypes. In contrast, gene
expression was not as obviously distinct, demonstrating for the first
time in a practical manner that these 2 methods of interpreting
transcriptional programming are complementary and when com-
bined can most robustly identify new disease subtypes.
One remarkable finding in the CEBPAsil cases was that their
unique DNA methylation signature consisted almost entirely
of hypermethylation of hundreds of loci compared with their
CEBPAmut counterparts. By chance, one would expect a more or
less balanced distribution between hypermethylation and hypo-
methylation, as observed in the comparison between CEBPAmut
cases and normal CD34 cells. The greater tendency toward
hypermethylation of these leukemias with silenced CEBPA was
further confirmed by the comparison of the CEBPAsil subgroup with
normal CD34 hematopoietic cells. Together, this suggests epige-
netic deregulation to play a more critical role in leukemogenesis of
those cases than of CEBPAmut cases. Such a hypothesis is supported
by our observation of involvement of a majority of the members of
gene regulatory networks centered around the CEBPA, NFB, and
BMP pathways, all implicated in the normal homeostasis of
hematopoietic stem cells and the myeloid lineage.
When DNA methylation profiles and gene expression profiles
were queried by supervised analysis, 474 and 415 genes were
identified as significantly differentially methylated or differentially
expressed, respectively. Yet there was only minimal overlap
between these 2 gene lists. This is consistent with our previous
observation that gene expression and DNA methylation array
studies capture different sets of genes and thus are complementary
to each other when collecting information on biologic variance.18
The fact that expression of more than 60% of the genes in the
hypermethylated signature was not detected in both groups partly
explains this finding because differences in low abundance tran-
scripts may be hard to detect by expression arrays. Despite all these
technical limitations, we still observed a greater tendency to overall
inverse correlation between gene expression and DNA methylation
status among those genes whose methylation status varied between
the 2 groups. This result suggests that the biologic impact of
epigenetic modifications may vary between gene subsets. Although
this has been shown for specific histone modifications, such as the
association between HOX cluster genes and methylation of lysine
27 on histone 3,39,40 a similar situation has not been previously
shown for cytosine methylation beyond that of its distribution
relative to CpG islands.
Although the existence of a hypermethylated phenotype in
CEBPAsil immature acute myeloid/T-lymphoid leukemia could be
related to a relatively more immature cell type involved in the
leukemic transformation, an alternative explanation could lie in
leukemia-specific mechanisms. The latter either could involve a
global up-regulation of DNA methylation machinery, leading to
more or less uncontrolled hypermethylation of multiple loci, or,
alternatively, could be a specific effect of targeted methylation of
selected genes. We took several approaches to investigate the
various possibilities. Comparative analyses between the 2 leuke-
mia subgroups and immature CD34 control samples from healthy
individuals indicated indeed a greater state of hypermethylation in
the CEBPAsil leukemia blasts than in normal CD34 cells. This is
suggestive for the idea that hypermethylation is not primarily a
read-out for cellular maturation status. In contrast, CEBPAmut
AMLs had markedly fewer hypermethylated genes compared with
CD34, indicating that an increase in DNA methylation is not a
general feature of all AMLs. Interestingly, mRNA expression levels
of the de novo DNA methyltransferase DNMT3B were significantly
increased in CEBPAsil versus CEBPAmut leukemias but showed
Figure 6. CEBPAsil leukemia cells are resistant to
myeloid growth. Tritiated thymidine incorporation experi-
ment of 3 CEBPAsil and 7 CEBPAmut leukemia samples.
Response of leukemia cells to IL-3, GM-CSF, and G-CSF
is shown relative to irradiated nonstimulated cells (ie,
stimulation index), based on the mean of 3 measure-
ments.
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similarly high levels in normal CD34 cells (data not shown).
Thus, although expression of methylating enzymes may be high in
healthy immature cells as well, this does not necessarily lead to a
similar hypermethylated signature as found in the leukemic sub-
group. There were no differences in expression of other DNA
methyltransferases (data not shown).
Specific targeting of methylation to certain genes by complexes
involving DNA methyltransferases and transcription factors has been
shown previously.41 Inversely, it could be hypothesized that loss of
protective mechanisms, such as DNA-binding proteins and nucleosome
positioning, could render certain promoters susceptible to the targeting
by the DNA methylation machinery.42 A common characteristic of the
leukemia subgroup studied here was silencing of the transcription factor
C/EBP. Using algorithms for motif analysis comparing significantly
hypermethylated genes with control genes, we were unable to detect a
significant enrichment for C/EBP binding sites among these genes,
arguing against a direct role for the absence of C/EBP. These analyses
did, however, yield 2 potentially relevant findings. First, we identified
enrichment of a novel sequence motif. This sequence could possibly
play a role in either directing the binding certain protein complexes to
DNA or in helping determine nucleosome positioning. Second, a
significant depletion of Alu repeats was detected in the promoters of
differentially methylated RefSeq genes. Although the causes behind
such a finding can only be speculated on, similar observation have been
made in the past, suggesting that this is probably not a random finding.43
CEBPAsil leukemias were previously found to have a mixed
myeloid/T-lymphoid phenotype. We were therefore interested to
determine how their DNA methylation profiles related to those
from T-ALL samples. Comparisons of the DNA methylation and
expression profiles of a representative collection of 9 T-ALL cases,
ranging from very immature to mature, to those of the CEBPAsil
leukemias revealed significant differences between the 2 types of
leukemias. This is consistent with the idea that CEBPAsil leukemias
represent an entity not entirely myeloid but also not entirely
T-lymphoid and may represent a very immature myeloid/T-
lymphoid subtype that is in current clinical practice sometimes
diagnosed as AML and sometimes as T-ALL.
The discovery of a hypermethylation profile in a specific
leukemia subgroup is particularly interesting in light of the recent
developments of demethylating drugs. Notably, the CEBPAsil
leukemia subgroup showed a markedly worse treatment response
than CEBPAmut AML.16 Interestingly, this is in contrast with the
previous report by Hackanson et al, who found that methylation of
CEBPA was associated with favorable prognostic groups in AML.13
However, the cases reported by that group all displayed methyl-
ation restricted to an upstream region of the CEBPA locus, whereas
the methylation in our samples was more extensive, covering both
proximal and distal regions. Although the numbers are small and
multivariable analysis with additional covariates such as cytoge-
netic and molecular subgroups is warranted, these results identify
CEBPAsil leukemia cases as attractive candidates for investigative
treatment with such demethylating agents. It is interesting to
speculate that restoring the normal programming of CEBPA, NFB,
and BMP pathways could facilitate targeting of these tumors with
either standard antileukemia regimens or with specific targeted
therapy agents.
Taken together, we show that integrated epigenetic and gene
expression analyses of leukemia can distinguish and illustrate
phenotypes with biologic and potential clinical significance. Analy-
sis of the genes involved in aberrant epigenetic programming
allows for generation of hypotheses toward dissecting previously
unrecognized mechanisms of leukemogenesis. A broader applica-
tion of integrated gene expression and epigenetic profiling to acute
leukemia might allow many other such entities to be resolved.
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